Leerink analyst Joseph Schwartz notes BioMarin (BMRN) believes INZ-701 could be a $400M-$600M opportunity at peak, making it ...

The Department of Health and Human Services will aim to negotiate drug prices down to the lowest prices paid by peer nations, ...

The Trump administration just dropped a bomb on Big Pharma. In a bold new move, the U.S. Department of Health and Human ...

Tourmaline Bio is well-funded, with cash runway into 2H 2027, minimizing near-term dilution risk for investors. Click here to ...

Fintel reports that on May 14, 2025, Leerink Partners downgraded their outlook for iTeos Therapeutics (NasdaqGM:ITOS) from ...

The new data from PureTech come after the company reported successful results from the phase 2b Elevate study in December ...

UnitedHealth Group said 2025 revenue at Optum would be $10 billion less than previously estimated. Now the company is saying ...

Pfizer will pay China’s 3SBio $1.25 billion upfront to gain access to a cancer therapy that could rival Akeso and Summit’s ...

Markets expect rate cuts — but your earnings don’t have to suffer. Lock in 7.2% until 2028 from ten individual bonds. Based ...

Boehringer Ingelheim’s long-awaited phase 3 lung disease data received a muted reception from analysts who labeled ...

While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the ...

The US Department of Health and Human Services is demanding that pharmaceutical companies cut drug prices to the lowest price ...